Compare Ecolab Inc. (ECL) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Enveric Biosciences Inc — how do they compare? Ecolab Inc. trades at $281.36 (market cap $78.97B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.80M). The key difference: Ecolab Inc. is far larger — about 11613.2× Enveric Biosciences Inc's market cap, and Ecolab Inc. pays a 1.04% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 90 Days and Enveric Biosciences Inc for 14 Days on average.
| ECL | ENVB | |
|---|---|---|
Market Cap | $78.97B | $6.80M |
Volume | 974,947 | 64,867 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $10.80 |
52-Week Low | $245.73 | $1.27 |
Typical Hold Time | 90 Days | 14 Days |
Enterprise Value | $87.75B | -$1.49M |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $278.10, down 0.97% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported $16.08B in 2025 revenue, with a net income margin of 12.57% and strong profitability metrics. Recent news highlights its dividend aristocrat status and growth in high-tech segments, while institutional buying and insider purchases reflect confidence.
Outlook remains positive with a consensus price target of $326.38, implying 17% upside, supported by analyst buy ratings (78%). Risks include elevated valuation multiples and increased debt from the CoolIT acquisition. Earnings growth in high-tech and digital segments is a key catalyst, though cost fluctuations pose headwinds.
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
